A recent study in support of similar synergy proposed the combination of KRAS-G12C plus mTORC1/2 inhibitors which reliably suppressed pERK and pAKT and induced cell death in pancreatic cancer models [103]. Here, KRAS is linked to pancreatic neoplasm.